MRNA - Moderna, Inc.

Moderna is a biotechnology company specializing in messenger RNA (mRNA) medicines. Their core business model revolves around leveraging their innovative mRNA technology to develop vaccines and therapeutics across various therapeutic areas, including infectious diseases, oncology, and rare genetic disorders. They gained prominence with the successful development of the Spikevax COVID-19 vaccine, which was one of the first and most effective vaccines against the virus. The company has a broad pipeline consisting of 45 programs, nine of which are in late-stage development, and continues to expand beyond COVID-19 into other diseases and conditions with significant unmet needs.

In addition to infectious disease vaccines, such as those for RSV and seasonal flu, Moderna is exploring cancer immunotherapies through individualized neoantigen therapies (INTs) and treatments for rare diseases. Their strategy involves continuous investment in expanding their mRNA platform and harnessing digital technologies, including artificial intelligence, to enhance drug discovery and manufacturing processes. As they transition from pandemic-focused vaccine sales to a broader portfolio, they are also restructuring their manufacturing capabilities to ensure profitability in an increasingly competitive landscape.